Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CompassHER2-pCR in HER2-positive breast cancer
NCT04266249Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Mar 2020
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of Paclitaxel Micelles for Injection, trastuzumab, pertuzumab in breast cancer, sponsored by ECOG-ACRIN Cancer Research Group. Started Mar 2020; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04266249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266249.